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Abstract
The immunomodulatory drug lenalidomide (Len) has drawn attention to potentiate antibody-dependent cellular
cytotoxicity (ADCC)-mediated immunotherapies. We developed the defucosylated version (YB-AHM) of humanized
monoclonal antibody against HM1.24 (CD317) overexpressed in multiple myeloma (MM) cells. In this study, we evaluated
ADCC by YB-AHM and Len in combination against MM cells and their progenitors. YB-AHM was able to selectively kill via
ADCC MM cells in bone marrow samples from patients with MM with low effector/target ratios, which was further enhanced
by treatment with Len. Interestingly, Len also up-regulated HM1.24 expression on MM cells in an effector-dependent
manner. HM1.24 was found to be highly expressed in a drug-resistant clonogenic ‘‘side population’’ in MM cells; and this
combinatory treatment successfully reduced SP fractions in RPMI 8226 and KMS-11 cells in the presence of effector cells,
and suppressed a clonogenic potential of MM cells in colony-forming assays. Collectively, the present study suggests that
YB-AHM and Len in combination may become an effective therapeutic strategy in MM, warranting further study to target
drug-resistant MM clonogenic cells.
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Introduction
Multiple myeloma (MM) is characterized by the accumulation
of neoplastic plasma cells in the bone marrow [1]. Hematopoietic
stem cell transplantation and novel agents such as bortezomib,
thalidomide, and lenalidomide (Len) have improved survival in
MM patients [2,3]. However, most patients eventually relapse
even after the achievement of complete response [4]. Recent
studies suggested the presence of MM cancer stem cells (CSCs) or
MM initiating cells with dormancy, self-renewal, and resistance to
chemotherapeutic agents is responsible for recurrence of the
disease [5]. Therefore, the development of novel therapies
targeting MM CSCs is needed to further improve the prognosis
of MM patients. We are currently focusing on the development of
monoclonal antibody (mAb)-based immunotherapies that can
target MM CSCs. Our recent study has shown that a small
molecule antibody specific to human leukocyte antigen (HLA)
class I can inhibit side population (SP) cells with the characteristics
of CSCs in MM which express high levels of HLA [6]. This result
suggests that mAbs against surface molecules commonly shared by
MM cells and their progenitors are able to impair clonogenic MM
cells or MM CSCs, although MM CSCs are resistant to
chemotherapeutic agents.
MAb-based immunotherapy has become an alternative strategy
for the treatment of cancers [7]. In MM, the efficacy of mAbs that
target CD38 [8–11] and CS1 [12–16] has been reported. We
generated a mouse mAb specific to HM1.24 (CD317 or bone
marrow stromal antigen 2: BST2) by immunization with the
human myeloma cell line KPC-32 as described previously [17].
Although HM1.24 directly binds to immunoglobulin-like tran-
script 7 (ILT7) protein and initiates signaling via the ILT7- FceRIc
complex, the function of HM1.24 in MM cells is still not clear
[18,19]. However, this antibody significantly inhibited MM tumor
growth and prolonged survival in human MM-bearing xenograft
models [20]. Subsequently, we developed a humanized anti-
HM1.24 mAb (AHM) (IgG1k), which induces antibody-dependent
cellular cytotoxicity (ADCC) against MM cells in the presence of
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human effector cells [21,22]. A phase 1 study of AHM showed that
although adverse events were mild and manageable, clinical
efficacy was limited to be 7% in partial response in heavily treated
patients with relapsed or refractory MM [23], which may be at
least in part due to insufficient function and numbers of effector
cells in those patients. Therefore, we have generated a defucosy-
lated version of AHM (YB-AHM) with higher binding ability to
Fcc receptor (FccR) IIIa to effectively elicit ADCC with smaller
numbers of effector cells [24].
Len is one of the potent immunomodulatory drugs (IMiDs) that
is getting widely used in patients with newly diagnosed and
refractory or relapsed MM with encouraging outcomes.[25–27]
Len induces not only direct cytotoxic effects on MM cells but also
immunomodulatory, anti-inflammatory, and anti-angiogenic ef-
fects on accessory cells surrounding MM cells in the bone marrow
[28]. In particular, Len stimulates the activity of NK cells and
enhances their ADCC activity [28], and has been combined to
potentiate the clinical efficacy with various mAbs, including anti-
CD38, anti-CS1 and anti-CD20 [10,13,29]. Recently, Tai et al.
have shown that Len significantly enhances the anti-MM activity
of an Fc-engineered humanized anti-HM1.24 mAb in vitro and in
vivo [30]. The Fc-engineered AHM is a mAb with 2 amino acid
substitutions (S239D/I332E) in the IgG1 Fc portion of AHM,
while YB-AHM is generated by removing the fucose moiety in the
IgG1 Fc portion of AHM to enhance its binding to FccRIIIa. The
combination effects of Len and anti-HM1.24 mAb on MM
progenitors or CSCs have not been elucidated.
In this study, we investigated the efficacy of a defucosylated
humanized anti-HM1.24 mAb, YB-AHM, in combination with
Len against MM cells in bone marrow mononuclear cells
(BMMCs) from patients with MM which contain substantial
MM cells with relatively smaller numbers of effector cells, and the
potential of this combinatory strategy to target clonogenic MM
cells.
Materials and Methods
Patients
The diagnosis and clinical staging of MM were performed based
on the criteria of International Myeloma Working Group (IMWG)
[1], Durie and Salmon staging system (D&S) [31], and interna-
tional staging system (ISS) [32]. A total of 26 treated or untreated
MM patients (19 males and 7 females) were included in this study.
The mean age was 70.7 year-old (range, 54 to 85). Clinical stages
were as follows, ISS I, 11%; II, 54%; III, 35%, D&S I, 4%; II,
31%; III, 65%. Monoclonal immunoglobulins in serum or urine
were found in 24 patients: IgG, 71%; IgA, 17%; light chain only,
12%.
Cells
All procedures involving human samples from healthy donors
and patients were performed with written informed consent
according to the Declaration of Helsinki and using a protocol
approved by the Institutional Review Board at University of
Tokushima (Tokushima, Japan) (Permit number: 1434). Peripheral
blood mononuclear cells (PBMCs) were obtained from 5 healthy
donors and 21 patients with MM. BMMCs including MM cells
were obtained from the bone marrow of 16 patients. PBMCs and
BMMCs were isolated by Ficoll density gradient centrifugation
(Ficoll-Paque PLUS, GE Healthcare Bio-sciences AB, Uppsala,
Figure 1. Enhancement of ADCC activity by YB-AHM and PBMCs pretreated with Len. (A) RPMI 8226, U266, and OPM-2 MM cell lines, and
the control HEL leukemic cell line, were incubated with PBMCs from a healthy donor for 4 hours at an E/T ratio of 10 in the presence AHM (#) or YB-
AHM (X) at various concentrations as indicated. The viability of target cells was analyzed by a flow cytometric PKH26 assay. ADCC activity was
determined by percentages of 7AAD+ dead cells in PKH26-labeled target MM cells. (B) RPMI 8226 cells were incubated with PBMCs from a healthy
donor for 4 hours in the presence of 0.1 mg/mL of AHM (#) or YB-AHM (X) or absence (&) at various E/T ratios as indicated. (C) PBMCs from 3
normal donors were cultured alone or in the presence of Len (3 mM) for 48 hours. These PBMCs were added to PKH26-labeled RPMI 8226 cells at an E/
T ratio of 10 in the presence or absence of AHM (0.1 mg/mL) or YB-AHM (0.1 mg/mL) for 4 hours. (D) PKH26-labeled RPMI 8226 cells were incubated in
triplicate with Len-treated or untreated PBMCs from a patient with MM at an E/T ratio of 10 in the presence or absence of YB-AHM (0.1 mg/mL) for
4 hours. Representative flow cytometric result is shown (left). PKH26-labeled RPMI 8226 cells were distributed in red squares. (E) PKH26-labeled RPMI
8226 cells were incubated with Len-treated or untreated PBMCs from 3 patients with MM at an E/T ratio of 10 in the presence or absence of YB-AHM
(0.1 mg/mL) for 4 hours. Data presented are mean 6SD (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0083905.g001
Table 1. The characteristics of BMMCs from patients with MM.
Patient M-protein D&S ISS Plasma cell (MM cell) (%) Lymphocyte (%) Lymphocyte/MM cell
1 BJ-k IIA II 67.8 6.8 0.10
2 IgA-l IIIA I 9.6 2.4 0.25
3 IgA-l IIIA III 45.3 8.3 0.18
4 IgG-k IIIA II 42.2 7.2 0.17
5 IgG-l IIA II 14.4 13.4 0.93
6 Non-secretory IIIB III 45.8 10.2 0.22
7 IgG-k IIIA III 26.2 6.6 0.25
8 IgG-l IA II 24 13.2 0.55
9 IgG-l IIA II 18.8 13.6 0.72
10 IgG-k IIA I 29.2 9.4 0.32
D&S indicates Durie and Salmon staging system; ISS, international staging system.
Patients with MM included incipient or relapsed stage. D&S was distributed as follows: IA, 10%; IIA, 40%; IIIA, 40%; IIIB, 10%. ISS was distributed as follows: I, 20%; II, 50%;
III, 30%. The average ratio of lymphocyte/MM cell was 0.48.
doi:10.1371/journal.pone.0083905.t001
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Sweden). These cells were used with or without treatment with
Len. Len was kindly provided by Celgene Corporation (Morris,
NJ, USA)
The human MM cell lines, RPMI 8226, U266, OPM-2, and
KMS-11, were obtained from the American Type Culture
Collection (Rockville, MD, USA). The erythroid leukemia cell
line HEL was from the Japanese Cancer Research Resources Bank
(Tokyo, Japan) and used as a negative control because HEL cells
did not express the HM1.24 antigen. Cells were cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum,
penicillin (100 U/mL) and streptomycin (100 mg/mL).
Flow cytometry
The expression of HM1.24 antigen on MM cells was analyzed
by flow cytometry. Cells were stained with fluorescein isothiocy-
anate (FITC)-labeled anti-HM1.24 [17]. BMMCs were stained
with PE-conjugated anti-CD38 mAb (BD Biosciences), and MM
cell fraction was determined according to side scatter and CD38
profiles. The expression of cell surface antigens on SP cells and
Figure 2. Combination of YB-AHM plus Len enhanced cytotoxicity against MM cells in BMMCs from MM patients. (A) BMMCs from a
MM patient (no. 3) were pretreated with or without Len (3 mM) for 24 hours, and incubated in the presence of AHM or YB-AHM (0.1 mg/mL) for
24 hours. Thereafter, the cells were stained with control PE-labeled mouse IgG or PE-labeled CD38 mAb, and analyzed by flow cytometry. MM cell
populations were indicated within squares according to side scatter (SS) and CD38 expression profiles. (B) Cytotoxic activity was estimated by %
increase of dead cells from the baseline of CD38++ MM cell fractions in BMMCs from MM patients (n = 10). Data presented are mean6SD (**, p,0.01).
(C) BMMCs from a MM patient (no. 5) were treated with or without Len (3 mM) and YB-AHM (0.1 mg/mL) as above. Cytospun preparations were
stained with a Wright-Giemsa solution, and examined under a microscope (original magnification, x 1000).
doi:10.1371/journal.pone.0083905.g002
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main population (MP) cells was analyzed by flow cytometry using
FITC- or PE-conjugated anti-ABCG2 (Chemicon, Temecula, CA,
USA), anti-ABCB1 (Beckman Coulter), anti-CD138 (BD Biosci-
ences), and anti-HM1.24 mAb.
ADCC assays
Target MM cells were stained with PKH26 (Sigma) according
to the manufacturer’s instruction. Effector to target (E/T) ratios
were tentatively determined in this study as the ratios of PBMC/
MM cell numbers. The target cells were mixed with PBMCs at
various E/T ratios and further incubated in the presence of mAb.
To identify dead cells, the cells were incubated with 7-
aminoactinomycin D (7AAD, Beckman Coulter, Brea, CA,
USA) for 30 min, and then analyzed by flow cytometry. The
ADCC (%) was expressed as the percentage of 7AAD-positive cells
within PKH26-labeled MM cells.
SP analysis and sorting
A SP analysis was performed as previously described [33].
Briefly, cells were incubated with 5 mg/mL Hoechst 33342 (Sigma)
for 90 min at 37uC in phosphate-buffered saline containing 3%
fetal bovine serum in the presence or absence of 100 mM
verapamil (Sigma). Then, the cells were washed and incubated
with propidium iodide (PI, 1 mg/mL) to discriminate dead cells.
SP analysis and sorting were performed using a cell sorter
(Beckman Coulter).
Colony formation assay
MM cells were cultured in the presence or absence of YB-AHM
and Len -pretreated PBMCs for 24 hrs. The cells were plated out
into H4034 methylcellulose medium (Stem Cell Technologies,
Vancouver, BC, Canada) in triplicates for 14 days. MM cell
colonies with more than 40 cells were counted under an inverted
microscope [34].
Statistical analysis
The statistical significance of the obtained values was analyzed
by repeated measure ANOVA, using Turkey’s post hoc multiple
comparison tests. P-values below 0.05 were considered as
significant.
Results
ADCC activity of YB-AHM was augmented by Len in the
presence of PBMCs
First, we examined the ADCC activity of AHM and YB-AHM
against MM cell lines in the presence of PBMCs from healthy
donors. YB-AHM induced cytotoxicity more effectively than
AHM against RPMI 8226, U266, and OPM-2 cells in a dose-
dependent and an E/T ratio-dependent manner (Figure 1A and
1B). The cytotoxic effects of these antibodies were not observed
against HEL leukemic cells without expressing HM1.24. The
ADCC activity of YB-AHM was further enhanced by Len-treated
PBMCs from normal donors compared to those without Len
treatment (13.066.7% vs. 25.665.1%, p,0.05) (Figure 1C). The
ADCC activity by Len-stimulated PBMCs was significantly higher
with YB-AHM than AHM (25.665.1% vs. 9.664.5%, p,0.05).
We next evaluated whether pretreatment of PBMCs with Len
further enhances the ADCC activity of YB-AHM. Figure 1D
depicts a representative distribution of dead MM cells in flow
Figure 3. Len enhanced the HM1.24 expression on primary MM cells in the presence of effector cells. (A) RPMI 8226 cells were cultured
for 48 hours in the absence (black) or presence of 3 mM Len alone (blue), or 3 mM Len plus PBMCs from a healthy donor using membrane filters to
avoid cell contact (red). (B) BMMCs from MM patients (no. 11, 12, and 13) were cultured for 48 hours in the absence (black) or presence of 3 mM Len
(red). Thereafter, the MM cells were stained with control FITC-labeled mouse IgG or FITC-labeled HM1.24 mAb, and PE-labeled CD38 mAb, and
analyzed by flow cytometry. MM cells were gated according to a side scatter (SS) and CD38 expression, and analyzed for their HM1.24 expression.
doi:10.1371/journal.pone.0083905.g003
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Figure 4. Combination of YB-AHM plus Len induced ADCC activity against SP cells. (A) SP and MP fractions were isolated from RPMI 8226
cells by a cell sorter, and the expression of ABCG2, ABCB1, CD138 and HM1.24 was analyzed by flow cytometry. RPMI 8226 and KMS-11 cells were
mixed with PBMCs from 3 healthy donors at the E/T ratio of 5, and treated with Len (3 mM) or YB-AHM (0.1 mg/mL) alone or both in combination for
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cytometric analysis. YB-AHM increased 7AAD+ dead cells (dead
target cells) within PKH26-labeled RPMI 8226 cells from 26.2%
to 47.1% and from 31.6% to 62.9% in the presence of non-
stimulated and Len-stimulated PBMCs from a patient with MM,
respectively. YB-AHM-induced ADCC was further confirmed to
be enhanced by the Len pretreatment of PBMCs from 3 patients
with MM (Figure 1E).
Combination of YB-AHM plus Len enhanced cytotoxicity
against MM cells in BMMCs from patients with MM
As shown in Figure 1B, the ADCC activity of YB-AHM is
dependent on E/T ratios. However, the ratios of lymphocytes/
MM cells were found to be low from 0.1 to 0.93 with an average of
0.48 in BMMCs from 10 patients with MM (Table 1). Especially,
in newly diagnosed and relapsed cases with advanced stages, MM
cells often comprise a large population in BMMCs to reduce their
E/T ratios, which may limit the induction of ADCC activity
against MM cells in the bone marrow. We therefore asked whether
the combinatory treatment with Len and YB-AHM is able to
induce ADCC against MM cells in BMMCs from patients with
MM. Figure 2A showed a representative case (no. 3) with the
effective reduction of MM cells by treatment with Len followed by
YB-AHM. CD38++ MM cell fractions were reduced to 7.94% and
6.15% after treatment with AHM and YB-AHM, respectively,
from 10.8% at the baseline. Len alone or in combination with
sequential AHM treatment slightly reduced the MM fractions to
be 9.7% and 5.38%, respectively. However, treatment with Len
followed by YB-AHM markedly decreased the viable MM cells to
0.54%, although the lymphocyte/MM cell ratio of the BMMCs
was 0.18 in this case. We further examined the cytotoxic effects of
the above combinatory treatments on MM cells using BMMCs
from the 10 patients. Len pretreatment tended to increase the
cytotoxic activity of AHM (22617% vs. 7610%), but significantly
enhanced that of YB-AHM (46623% vs. 19615%, p,0.01)
(Figure 2B). In specimens cytospun after the Len and YB-AHM
treatment, lymphoid cells were observed to attach to MM cells,
implying a close interaction between these cells (Figure 2C lower).
These results demonstrate that Len is able to induce ADCC
activity with YB-AHM against MM cells in BMMCs with low E/T
ratios from patients with MM.
Len up-regulated HM1.24 expression on MM cells in the
presence of effector cells
To clarify the mechanisms by which Len enhances the ADCC
activity of YB-AHM, we next looked at the effects of Len on the
surface expression of HM1.24 in MM cells. Len did not directly
up-regulate the HM1.24 expression on RPMI 8226 cells cultured
alone (Figure 3A). However, when the MM cells were co-cultured
with PBMCs on membrane filters to prevent their contact to MM
cells, Len enhanced the HM1.24 expression on the surface of
RPMI 8226 cells, suggesting the role of soluble factors elaborated
from non-MM mononuclear cells by Len. Consistently, Len
enhanced the expression of HM1.24 on MM cells in BMMCs
from patients with MM (Figure 3B). Because the surface levels of
HM1.24 have been demonstrated to correlate well with the
cytotoxic activity of AHM or YB-AHM against MM cells [35,36],
the up-regulation of HM1.24 expression on the surface of MM
cells may contribute to the enhancement of ADCC by YB-AHM
plus Len treatment.
Combination of YB-AHM plus Len reduced SP cells
To determine whether the combination therapy with YB-AHM
plus Len affects MM drug-resistant SP fractions, we first examined
the expression levels of HM1.24 in SP and MP fractions of MM
cells. SP fractions isolated from RPMI 8226 cells expressed higher
levels of the ABC transporter ABCG2 but not ABCB1 than MP
fractions, and contained CD138low populations (Figure 4A).
However, SP fractions equally expressed HM1.24 at high levels
as MP fractions. Next, we examined the ADCC activity with YB-
AHM and Len against SP fractions. RPMI 8226 and KMS-11
cells exhibited SP fractions (Figure 4B). These cells were mixed
with PBMCs from 3 normal donors, and treated with Len, YB-
AHM alone, or both in combination. Although Len alone did not
reduce the percentages of SP fractions in these cells, YB-AHM
substantially decreased the SP fractions (Figure 4C). Further
reduction in a SP size was observed with Len in RPMI 8226 cells.
Combination of YB-AHM plus Len suppressed colony
formation of MM cells
Because the treatment with YB-AHM plus Len effectively
reduced SP fractions which contain clonogenic MM cells [6,37],
we next examined the effect of YB-AHM and Len in combination
on colony formation of MM cells by methylcellulose assays. RPMI
8226, U266, and OPM-2 cells formed colonies as observed under
a microscope (Figure 5A). YB-AHM significantly reduced the size
and the numbers of colonies in all the cell lines (Figures 5A and
5B).
Discussion
In this study, we demonstrated that YB-AHM significantly
induces ADCC activity against MM cells in the presence of
effector cells, which is further enhanced by treatment with Len in
combination. The binding of mAb to cognate FccRs of effector
cells is critical for ADCC. YB-AHM is defucosylated to enhance its
binding to FccRs, and induced ADCC against MM cells more
effectively than its prototypic AHM. We have demonstrated that
because of its high binding capacity to its cognate FccRs, YB-
AHM is able to induce ADCC irrespective of allelic variations of
FccRs [24], although clinical response of mAbs such as rituximab
has been shown to be associated with a polymorphism of FccRIIIa
[38–40]. In addition, Len has been demonstrated to enhance
ADCC via the activation of effector cells. Indeed, Len was able to
enhance the ADCC activity of YB-AHM against primary MM
cells in patient-derived BMMCs with relatively lower E/T ratios.
Therefore, YB-AHM in combination with Len is thought to be
applicable to most MM patients.
HM1.24 expression level on MM cells is another key issue. We
observed that Len up-regulated the expression of HM1.24 on
primary MM cells via the interaction with effector cells in contrast
to the down-regulatory effect of Len on CD20 expression in B cell
lymphoma [41]. The promoter region of HM1.24 gene contains
the interferon (IFN)-stimulated response elements such as inter-
feron related factor (IRF)-1/2 and interferon-stimulated gene
factor (ISGF) 3, and IFN is able to enhance the HM1.24
expression [36,42]. Len has been demonstrated to induce the
24 hours. Then, flow cytometric SP analysis was performed. SP fractions were determined by Hoechst 33342 dye staining with verapamil, and gated
as indicated. (B) Representative flow cytometric results are shown. The percentages of SP fractions within whole living cells are shown. (C) % change
of SP fractions after the indicated treatments using PBMCs from 3 normal donors are shown. Data presented are mean 6SD (*, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0083905.g004
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production of cytokine such as IFN-c and IL-2 from effector cells,
which may contribute to the up-regulation of HM1.24 on co-
existing MM cells [43].
MM CSCs have been proposed to be responsible for drug
resistance and a relapse although they are not properly defined yet
[5]. SP cells are identified as a drug resistant fraction by their
ability to efflux a Hoechst 33342 dye, a substrate for the ATP-
binding cassette (ABC) transporter ABCG2 [44], and have been
reported to contain CSCs in many cancers._ENREF_45 We
found that HM1.24 was highly expressed on the surface of SP
cells, and that YB-AHM plus Len in combination effectively
reduced SP fractions in RPMI 8226 and KMS-11 cells (Figure 4B).
Further, this combination treatment inhibited the clonogenic
potential (Figure 5). Therefore, the combination therapy of YB-
AHM plus Len might become an effective strategy to target
putative MM CSCs.
In conclusion, we demonstrate that YB-AHM induces marked
ADCC activity against MM cells in combination with Len. The
present results warrant further study to determine whether this
combination strategy could target drug-resistant MM CSCs and
prevent a disease relapse in MM.
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Figure 5. Combination of YB-AHM plus Len inhibited clonogenecity of MM cells. PBMCs from 6 patients with MM were stimulated with or
without Len (3 mM) for 48 hours, and then co-cultured with RPMI 8226, U266, and OPM-2 cells in the presence of YB-AHM (0.1 mg/mL). Thereafter, the
cells were plated out in triplicate into methylcellulose media, and cultured for 14 days. The photos of colonies were taken under an inverted
microscope (A), and the numbers of colonies were counted (B). Data presented are mean 6SD (**, p,0.01).
doi:10.1371/journal.pone.0083905.g005
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